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ABSTRACT 
 
Brachytherapy is a sophisticated radiation method in which radioisotopes are placed 
inside or at a short distance from the tumour. The volume of tissue that receives the 
prescribed dose of radiotherapy is therefore fairly small compared with that used in 
standard radiotherapy techniques. In paediatric oncology, this method of radiation 
delivery can have a favourable effect on several undesirable long-term side-effects that 
sometimes develop in children who receive radiotherapy, such as growth retardation and 
development of second primary tumours. Here, we describe the rationale for use of 
brachytherapy in children with cancer, the methods of the different brachytherapy 
techniques available, and the results obtained with several brachytherapy regimens in 
expert institutions throughout the world. 
  
 
 
 
 
 
 
 
 
 
 
DEFINITIONS AND NOMENCLATURE 
 
Brachytherapy is a radiation technique in which radioisotopes are placed inside or at a 
short distance from the tumour (brachios means short in classic Greek). In intracavitary 
brachytherapy (used in gynaecological cancers), radioactive sources are placed inside 
body cavities, whereas in interstitial brachytherapy (used in soft-tissue sarcomas), 
radioactive material is placed directly through the tissues (figure 1). Radioactive sources 
can be either withdrawn after a specified dose has been delivered (temporary) or left to 
decay inside the body (permanent). Brachytherapy can also be classified according to 
the prescribed dose rate as high-dose-rate (>12 Gy/h), medium-dose-rate (2–12 Gy/h), 
or low-dose-rate (<2 Gy/h). Finally, pulsed-dose-rate brachytherapy refers to the 
administration of remote afterloading brachytherapy over a few minutes (pulse) per 
interval, typically 1–2 Gy every 1–4 h during several days, whereas intraoperative high-
dose-rate brachytherapy is the administration of a single dose of irradiation during the 
surgical procedure. 
 
The planning target volume refers to the volume of tissue that needs to be irradiated to 
ensure that the target receives the prescribed dose;1 the clinical target volume is the 
tissue volume presumed to contain microscopic disease at a specific probability level; 
and the irradiated volume refers to the volume of tissue that receives a dose of 
radiotherapy meant to be biologically relevant because of the inaccuracies of the 
radiation techniques. 
 
 
POTENTIAL ADVANTAGES OF BRACHYTHERAPY 
 
Brachytherapy differs from external-beam radiotherapy in ways that can be 
advantageous for children. For instance, the planning target volume in brachytherapy is 
smaller than that in external-beam radiotherapy. Because no allowances need to be 
made for movement of internal organs, movement of patients, or errors in set-up, the 
brachytherapy planning target volume closely approximates the clinical target volume. 
Furthermore, the irradiated volume is also smaller than that for external-beam 
radiotherapy because brachytherapy irradiates from the centre of the clinical target 
volume outwards and the dose falls off at a rate that is inversely proportional to the 
square of the distance. As a result, late complications with a strong relation to a dose–
volume effect, such as growth retardation2–4 or second primary tumours,5–13 can be kept 
to a minimum. Brachytherapy is also usually a much quicker treatment than external-
beam radiotherapy (ie, minutes or days vs weeks), and the shorter time of treatment 
allows this procedure to be integrated more easily than other radiation techniques into 
interdisciplinary treatment programmes with surgery and multiagent chemotherapy. 
 
 
TECHNIQUES USED IN CHILDREN 
 
The brachytherapy techniques used in children are similar to those applied in adults 
with some modifications because of anatomical constraints or to keep late complications 
to a minimum. Although no dosimetric system can be firmly advocated as the gold 
standard in the treatment of tumours in children, soft-tissue sarcomas in small children 
that are located in areas adjacent to crucial structures (eg, growth plates) can benefit 
from shorter intercatheter spacing and reduced margins around the clinical treatment 
volume. These two methods have been recommended by the American Brachytherapy 
Society.14 Use of small spaces between catheters keeps the amount of tissue volume that 
receives brachytherapy doses above the prescribed isodose as small as possible. 
Similarly, vaginal tumours in children are treated with smaller custom-made applicators 
than are those in adults; and, in addition, doses are prescribed closer to the surface. Nag 
and Tippin15 recommend that doses be prescribed at 2 mm depth for girls younger than 
1 year, at 3 mm for girls aged 1 to 3 years, at 4 mm for girls aged 3 to 6 years, and at 5 
mm for girls older than 6 years. This recommendation results in a vaginal mucosal dose 
of about 60 Gy for most patients. 
 
The type of brachytherapy used depends on the age of the patient and on the availability 
of equipment. Although the most common technique is low-dose-rate brachytherapy 
with iridium-192 that is afterloaded manually and removed after treatment, use of this 
technique has been associated with radiation exposure to the children’s caregivers when 
constant supervision is needed. For this reason, this technique is not ideal for treatment 
of very young children. Remote afterloading technology has been used to reduce the 
radiation exposure to caregivers, and other new modalities such as high-dose-rate, 
pulsed-dose-rate, and intraoperative high-dose-rate brachytherapy almost eliminate the 
risk of radiation exposure. Furthermore, the radioactive sources in this equipment are 
retracted into the main safe during planned interruptions or in the event of an accidental 
entry into the treatment room. Other radiation sources such as iodine-125 can be used as 
an alternative to 192Ir, especially in very young children, because of reduced radiation 
exposure to caregivers and to extremely radiosensitive structures (eg, gonads).16,17 In the 
use of 125I, thin sheets of lead applied over the treated area or standard lead aprons (0.25 
mm lead equivalent) can adequately shield visitors. Radioisotopes such as gold-198 and 
californium-252 have also been used infrequently. 
 
 
Low-dose-rate brachytherapy 
 
Temporary 
In interstitial low-dose-rate brachytherapy, plastic catheters are inserted into the target 
volume with the aid of bore needles, usually at the time of resection (open-cavity 
procedure). The clinical target volume is determined jointly by the surgical and 
radiation oncology teams. The tumour bed is also seen directly, thereby avoiding a 
geographical miss. The procedure can also be done postoperatively on superficial sites 
(closed-cavity procedure). The implantation is followed by a dosimetric analysis, 
usually with a set of orthogonal radiograph films or CT images, once the child is ready 
for transportation. Manual or remote afterloading of radioactive sources (usually 192Ir) is 
usually done 3–5 days after excision to allow healing to begin, as recommended by 
experts who have suggested that the rate of wound breakdown can be lessened by use of 
a delayed loading policy.18 In intracavitary brachytherapy, custom-built intracavitary 
vaginal applicators are generally used because standard-sized applicators are usually 
inappropriate for young girls. Unlike interstitial brachytherapy, low-dose-rate 
intracavitary brachytherapy for vaginal tumours is done post-operatively after healing is 
complete; and loading can therefore be done immediately with either 192Ir or caesium-
137 sources. 
 
If low-dose-rate brachytherapy is used as the only adjuvant radiotherapy, doses of 45–
60 Gy are commonly used with rates of 0.4–0.6 Gy/h over 4–6 days. If it is combined 
with 40–50 Gy of external-beam radiotherapy, then the dose is reduced to 15–25 Gy. 
 
 
Permanent 
In permanent interstitial brachytherapy, low-activity (0.45–0.60 U) 125I seeds are 
commonly used, which are usually embedded at 1.0 cm intervals in vicryl suture 
material and sewn directly into the tumour bed. If the target volume contains gross 
palpable tumour or if surgery is discouraged, the 125I seeds are inserted into the tumour 
through hollow needles.16 The low photon energy of 125I (28 KeV) makes admission to 
hospital, a shielded room, and strict visitor restrictions unnecessary; however, some 
mild radiation precautions are sometimes needed for accompanying women who are 
pregnant or for other children during the first few months after implantation. 
 
Because only a few children are given this technique, no prescription guidelines are 
followed universally. In interstitial brachytherapy, the dose is usually prescribed at the 
periphery of the implant (if no gross tumour is visible) or at the periphery of the gross 
tumour to make sure that the chosen clinical target volume or gross tumour volume 
receives at least the prescribed dose. This prescription isodose is called the reference 
isodose in the Paris System19 and the minimum target dose in the International 
Commission on Radiation Units (ICRU) and Measurements Number 58 
recommendations.20 The prescription isodose is usually a proportion of the dose reached 
at the centre of the implant, called basal dose in the Paris system or mean central dose in 
the ICRU Number 58 system. 
 
 
Pulsed-dose-rate or high-dose-rate temporary brachytherapy 
 
In pulsed-dose-rate and high-dose-rate brachytherapy, the catheters (or applicators) are 
inserted into the tumour site in the same way as in low-dose-rate brachytherapy. Most 
equipment used in these techniques now allows three-dimensional CT-based dosimetry 
(figure 2) with beam’s eye view and dose-volume histograms. Furthermore, one 
stepping source can be used in most remote-controlled afterloaders, allowing treatment 
to be optimised through the use of modifiable dwell times. The treatments are done over 
a few days in pulsed dose rate and over a few minutes in high dose rate. 
 
Because only a few children are given these techniques, no reliable prescription 
guidelines have been issued. The few centres that have reported treatment with high 
dose rate brachytherapy have used small fractions of 3–5 Gy with or without external-
beam radiotherapy. The dose is generally prescribed at 0.5 cm tissue depth for resected 
tumour beds and at the periphery of the target volume for gross tumour. For cylinders 
placed within the cavity, the dose can be specified at various depths depending on the 
age of the child and the diameter of the cylinder to limit the vaginal surface dose to 
acceptable levels. 
 
 
Intraoperative high-dose-rate brachytherapy 
 
Intraoperative high dose rate brachytherapy (figure 3) shares some of the advantages of 
open-cavity low-dose rate brachytherapy—eg, the clinical target volume is determined 
jointly by the surgical and radiation oncology teams, thereby reducing the risk of a 
geographical miss. Hollow plastic catheters are inserted into special flexible applicators 
that are secured onto the surgical surface. The treatment is delivered with one high-
activity 192Ir source. When the intraoperative high-dose-rate treatment is finished, the 
surgical team completes the surgical procedure. The main advantage of this technique is 
that unaffected tissues are either displaced from the irradiated area or shielded, if 
clinically applicable. Risk of catheter displacement is also reduced, since treatment is 
given in a short time to a patient who has been anaesthetised. Doses are usually 
restricted to 10–15 Gy prescribed to 0.5 cm depth within the target tissues because of 
the radiobiological disadvantage of using large single-dose fractions. If possible, 
intraoperative high-dose-rate brachytherapy should be combined with external-beam 
radiotherapy and not used on its own. 
 
 
Specialised brachytherapy techniques 
 
Ocular brachytherapy is a type of low-dose-rate temporary brachytherapy in which an 
eye plaque with radioactive material is placed on the episcleral surface of the eye. In 
children, this type of treatment has been used mainly in management of retinoblastoma. 
Plaques are usually made of gold or other shielding material that protects the retina and 
other structures adjacent to the tumour. Radioactive plaques are sewn onto the sclera 
lying over the tumour and are left in place until the prescribed dose has been reached, 
usually in 2–4 days. 125I is the preferred radioisotope in many institutions because it has 
a lower ratio of dose to depth than other radioisotopes such as cobalt-60 or 192Ir. This 
lower penetration keeps the irradiation of nearby eye structures to a minimum. 
Ruthenium106 plaques have also been used in treatment of selected shallower tumours. 
Typical brachytherapy doses for retinoblastoma are 35–55 Gy, which are prescribed to 
the tumour apex at a rate of 0.3–0.6 Gy/h. 
 
Intralesional or intracystic brachytherapy refers to the instillation of liquid radioactive 
compounds into the tumour. Different radioisotopes specially prepared for injection, 
such as yttrium-90, 198Au, and phosphorus-32, have been used. In children, this 
sophisticated technique has been used in management of craniopharyngiomas that are 
mainly cystic. Large radiation doses in the range of 150–250 Gy are prescribed at the 
cyst wall. Because of the proximity to crucial structures such as the optic chiasm and 
the hypophyseal stalk, only radioisotopes with a very short reach can be used. The pure 
β-emitters 32P and 90Y, which have average tissue penetrations of only 0.8 mm and 1.1 
mm, respectively, are the most frequently used radionucleides. 
 
 
DISEASE-SPECIFIC OUTCOMES 
 
Table 1 shows the results of studies of low-dose brachytherapy in children with brain 
tumours.21,22 Sneed and coworkers22 reported on 28 patients with brain tumours who 
were given either 192Ir or 125I permanent low-dose-rate brachytherapy with a CT/MRI 
stereotactic method, and found that the mean Karnofsky performance status was 88 (SD 
9) at the time of brachytherapy, 87 (7) at 3 years, and 87 (9) in the 11 patients alive at 
6–12 years’ follow up. None of these long-term survivors are dependent on steroids. 
 
Several studies23–25 have reported the outcomes for 27 girls with clear-cell 
adenocarcinoma of the vagina who were treated between 1972 and 1986 who received 
surgery with pelvic lymphadenectomy and then ovarian transposition. External-beam 
radiotherapy was then added in patients with bulky tumours, nodal involvement, or 
stage III–IV disease (table 2). 
 
Around 80% of children with craniopharyngioma have been shown to respond to 
treatment in two studies26,27 (table 2). In the first study,26 49 patients (15 of whom were 
younger than 16 years) were given stereotactic 32P intracavitary radiotherapy. The 
second study27 used intracavitary 32P or 90Y, and noted that the side-effects were 
consistent with damage to the brain stem or cranial nerves with intracystic radioisotopes 
(table 2). 
 
Intraoperative high-dose-rate brachytherapy has been used to improve local control in 
children with Ewing’s sarcoma and primitive neuroectodermal tumours (table 2).28–30 
Other studies31–36 have also shown no noticeable complications and similar rates of 
long-term local control after intraoperative high-dose-rate radiotherapy (table 2). 
  
In the study by Nakamura and colleagues,34 15 children with stage IV nasopharyngeal 
lymphoepithelioma and one with stage III nasopharyngeal lymphoepithelioma were 
given high-dose-rate brachytherapy between May, 1992, and May, 2000. Children 
received two sessions of high-dose-rate brachytherapy (5 Gy) 1 week apart prescribed at 
10 mm from the applicators. Most patients responded well (table 2). 
 
Most (86%) of the 141 patients in the study by Shields and colleagues35 received 125I 
eye plaques with a median brachytherapy dose of 40 Gy: 60 (29%) of 208 tumours were 
treated as first-line and 148 (71%) as salvage treatment. Recurrence was detected at a 
mean of 8 months (range 2–51). The St Jude series36 also reported excellent results for 
local control (table 2). 
 
Fontanesi and colleagues37 showed that of seven patients with primary 
rhabdomyosarcoma, four were given brachytherapy alone at a rate of 0.4–0.5 Gy/h, one 
was given brachytherapy alone at 1.2 Gy/h and the other two, who had gross residual 
disease, received brachytherapy combined with external-beam radiotherapy. Of the five 
patients given brachytherapy alone (patients treated at 1.2 Gy/h), one developed soft 
tissue necrosis and the other four patients had no noticeable complications; all were 
alive and had had no local recurrence at the latest follow-up. Neither of the patients with 
primary tumours given brachytherapy and external-beam radiotherapy achieved local 
control, and both died of disease. Of the seven patients with recurrent or metastatic 
rhabdomyosarcoma, six were given brachytherapy alone and one was also given 
external-beam radiotherapy. Five of the seven patients achieved local control, although 
five developed distant disease within 12 months. One patient developed vaginal 
necrosis and another started bleeding at the catheter site at the time of catheter removal. 
The only patient to survive longer than 12 months developed soft-tissue necrosis that 
needed treatment with hyperbaric oxygen. 
 
In a study by Curran and colleagues,38 patients who were given first-line treatment 
received 192Ir low-dose-rate brachytherapy only, two of three patients with recurrent 
disease after radiotherapy were given permanent implants and one was given temporary 
brachytherapy. Although most patients achieved local control (table 3), three died of 
disease. Chronic sequelae included telangiectasia and early tooth decay, fibrosis of the 
floor of the mouth with mild speech impairment, and shoe-size discrepancy. 
 
In a series of reports,28–30 20 children with rhabdomyosarcoma given intraoperative 
high-dose-rate brachytherapy were assessed. One patient developed an infarcted bowel 
about 1 year after surgery and received intraoperative high-dose-rate brachytherapy to 
the right buttock (15 Gy) and retroperitoneum (12 Gy) for an alveolar 
rhabdomyosarcoma. He also received postoperative external-beam radiotherapy to 45 
Gy. Another patient was diagnosed with hepatic veno-occlusive disease after 
intraoperative high-dose-rate brachytherapy to the porta hepatis followed by 24 Gy 
whole-abdominal radiotherapy for a massive retroperitoneal embryonal 
rhabdomyosarcoma. Nag and colleagues32,33 also reported on three patients with 
rhabdomyosarcoma involving the pelvic sidewall on one or both sides treated with 
intraoperative high-dose-rate brachytherapy and external-beam radiotherapy, although 
in one case, external-beam radiotherapy was not given. One patient with recurrent 
vaginal rhabdomyosarcoma in the inguinal and pelvic nodes needed orthopaedic 
pinning of her femoral subcapital epiphysis and construction of a neobladder secondary 
to ureteral obstruction. 
 
Table 3 shows the results of studies of brachytherapy in patients with 
rhabdomyosarcoma.2,23,25,28–30,32,33,37–47 In a prospective trial of high-dose-rate 
brachytherapy alone, three of the 12 very young girls with rhabdomyosarcoma had 
grade 3–4 morbidity, and three developed grade-2 morbidity.39,40 Vaginal stenosis 
developed 10 years later in one girl, and periurethral fibrosis developed 8 years later in 
another when they entered puberty. 
 
In a study43 of 20 children with primary head and neck non-orbital rhabdomyosarcoma, 
ten had non-surgical complications, including malocclusion in four children and atrophy 
of the muscle flap, rhinolalia aperta, articulation disorders, epiphora and dental 
problems, trismus, craniofacial asymmetry, and velopharyngeal insufficiency in the 
other six. In another report,42 patterns of failure were assessed in 24 patients with 
rhabdomyosarcoma (table 3). Most patients were treated with low-dose-rate 
brachytherapy, and some received pulsed-dose-rate brachytherapy. Five of the six 
patients who had relapse in the residual area had gross total or incomplete surgery, 
suboptimal position brachytherapy mold, or both. Long-term sequelae in a study by 
Buwalda and colleagues41 included mild swallowing disorders in one child; dental 
disturbances of multiple elements in three children, which were found in all four 
quadrants and without a preference for the site of the treated lesion; and trismus in one 
child. One patient developed a second primary cancer, a myofibrosarcoma originating 
within the treatment field, 7.8 years after brachytherapy treatment. 
 
Nag and colleagues23,44,45 reported that 18 of 23 children with bladder or prostate 
tumours were given low-dose-rate brachytherapy as first-line treatment and five 
received this technique as salvage treatment. Of the 18 patients treated with first-line 
brachytherapy, 11 are alive, ten with organ preservation (table 3). Of the five children 
given salvage brachytherapy, one had locoregional failure and one had distant failure; 
three patients are alive and without local failure at 4, 9, and 11 years follow-up. 
 
Gerbaulet and colleagues25,46,47 reported on 17 girls with rhabdomyosarcoma of the 
vagina treated with low-dose-rate brachytherapy (table 3). Before brachytherapy, eight 
patients underwent oophoropexy. 12 pubescent or postpubescent girls were investigated 
for long-term sequelae (follow-up longer than 10 years). 11 of the 12 patients have had 
a normal puberty, and two of them have had a total of three healthy children delivered 
by caesarian-section (these patients had not undergone ovarian transposition). One 
patient had a partial ovarian insufficiency (oophoropexy was not done) with an 
estimated dose to the bilateral ovaries of 10–15 Gy in 7 days. One patient underwent 
hysterectomy after low-dose brachytherapy. 11 patients had normal menses, and ten had 
normal menarche (one after hormonal replacement). Five girls had only minor 
telangiectasias; three are sexually active. Three have had minimal vaginal sequelae, 
which needed surgery to allow sexual intercourse. 15 of the 17 girls were cured of their 
disease. 
 
The largest series48 done in soft-tissue sarcoma included 27 children with primary 
disease and four with recurrent disease. The children were implanted with 125I or 192Ir in 
temporary or permanent implants. Of the 27 patients treated as first-line treatment, ten 
received brachytherapy alone and the remaining 17 were given brachytherapy and 
external-beam radiotherapy (table 4).23,48–51 
 
 
CONTROVERSIAL ISSUES 
 
The data presented in the previous section comprises the experience generated by a 
handful of expert institutions in a fairly small number of patients, and therefore the 
results are sometimes criticised for not having the necessary level of evidence needed in 
modern medicine. In fact, the level of evidence derived from the brachytherapy studies 
ranges from III to V, which corresponds to a grade C of recommendation for therapy.52 
This low level of evidence is not surprising, however, taking into account that the 
incidence of all types of cancer in children aged younger than 20 years during 2002 was 
16.5 per 100 000 people53 according to the US Surveillance, Epidemiology and End 
Results (SEER) programme, with soft-tissue sarcomas (International Classification of 
Childhood Cancers [ICCC] group IX)—the group in which brachytherapy experience is 
the largest—ranking fifth with an incidence of 1.1 cases per 100 000 and a proportion of 
less than 8% of all the tumours diagnosed in children. It should be noted that the use of 
brachytherapy in leukaemia (ICCC, group I), lymphomas and reticuloendothelial 
neoplasms (ICCC group II), and CNS and miscellaneous intracranial and intraspinal 
neoplasms (ICCC group III) that account for more than 60% of the cancers diagnosed in 
children is anecdotal.17,21,22 
 
However, brachytherapy has some potential advantages. The small size of the 
brachytherapy planning target volume could keep to a minimum the development of late 
complications that have a strong relation to a dose-volume effect such as growth 
retardation2–4 or second primary tumours.5–13 In fact, the literature reviewed14–17,21–51,54,55 
shows only one case43 of brachytherapy-induced second primary cancer. Whether this 
fact confirms the above-mentioned hypothesis or simply reflects the small number of 
patients treated is unclear. 
 
This finding could be especially important because second primary tumours are 
regarded as the most emotionally and physically devastating complication afflicting 
children who survive cancer.56 The cumulative incidence of second primary tumours in 
survivors of cancer in childhood is about 3%,9,10 a low incidence rate when the fact that 
more than 75% of children with cancer are expected to be long-term survivors is taken 
into account.53 
 
The risk of developing a radiation-induced second primary tumour is higher when 
treatment is delivered at a younger age,7 and the risk increases with longer follow-up. 
Radiation-induced second primary cancers usually occur after a long latency period 
(more than 10 years for bone tumours, 15–20 years for breast cancer), and the risk 
remains constant thereafter. Some tissues such as the female breast and the thyroid 
gland might be more sensitive to radiation and are at risk to develop second primary 
tumours at quite low doses; other tissues such as bone could be susceptible only at 
higher doses. The risk of development of second primary tumours of the female breast,5 
bone,8,12 and thyroid6 is known to be related to the dose of radiation delivered during 
childhood. For instance, the risk of development of second primary tumours of the bone 
is 40 times higher after doses of more than 60 Gy than after lower doses, and the 
relative risk of cancer of the female breast is 5.9 times higher after radiation doses of 
20–40 Gy than after doses of less than 20 Gy.5 As a result, external-beam radiotherapy 
techniques for cancer in childhood, such as those implemented by the Intergroup 
Rhabdomyosarcoma Study or by several Intergroups in Hodgkin’s lymphoma have 
gradually reduced the radiation volume and dose, and have moved towards a higher 
conformality;54 therefore, the current external-beam radiotherapy and brachytherapy 
approaches to treating cancer in childhood are quite similar. 
 
Because of the smaller clinical target volume irradiated with brachytherapy (figure 4), 
developing organs could be less susceptible to growth alteration than after conventional 
radiotherapy. Organ development depends not only on exposure to cytotoxic therapy 
but also on the type of organ architecture (ie, the possibility that the unaltered organ 
tissue compensates for the damage received to the altered fraction of the same organ) 
and on the stage of development at which the damaging event takes place. For instance, 
brain damage could be unrecoverable in patients aged younger than 7 years, a time at 
which CNS development is thought to be completed, but could be somewhat better 
tolerated in older children. Unfortunately, no randomised trials have compared 
brachytherapy and external-beam radiotherapy and focused on long-term complications. 
 
Another potential advantage of brachytherapy is the small size of the irradiated volume. 
Although as noted before, the radiation dose received during childhood is associated 
directly with the risk of developing a second primary cancer, other reports have 
questioned this fact. Dorr and Herrmann57 reported that about 80% of 203 radiation-
induced second primary tumours (across all ages) were seen in the volume receiving 
less than 6 Gy (2.5 cm inside to 5 cm outside the margin of the planning target volume). 
The brachytherapy clinical target volume will probably be even smaller in the future. 
Until recently, the generally accepted view of treating sarcomas in children with 
radiation was to cover large volumes with adequate margins.23–25 However, in some 
chemosensitive cancers in childhood, for example, rhabdomyosarcoma, such an 
approach might not be necessary. Data from institutions that do paediatric 
brachytherapy routinely suggest that radiotherapy of the postchemotherapy volume 
(figure 5) with 1–2 cm margins is adequate.15,46 Although no formal limits in terms of 
dose and volume exist in paediatric brachytherapy, limiting the volume implant to less 
than 50 mL and the total dose to less than 55–60 Gy would seem prudent. Investigators 
at the Institut Gustav Roussy recommend avoidance of large-volume high-dose implants 
(more than 70 Gy) and dose rates greater than 1 Gy/h. 
  
Furthermore, brachytherapy could also be integrated better into multidisciplinary 
programmes that include multiagent chemotherapy. Needless to say, chemotherapy is of 
paramount importance in many childhood tumours such as rhabdomyosarcoma, 
Ewing’s family, and others. Because of the short treatment time, brachytherapy could 
avoid harmful delays (that might be needed during external-beam radiotherapy) in the 
delivery of cytotoxic therapy because of unrecovered bone-marrow function. Such 
avoidance of delays could allow the dose intensity achieved with chemotherapy to be 
maintained or even increased. The amount of bone-marrow reserve is also surely higher 
after brachytherapy than after wide-field external-beam radiotherapy, which would 
allow effective cytotoxic retreatment in children who recur after initial treatment or in 
candidates for high-dose regimens with bone-marrow support. 
 
Finally, most of our current understanding of brachytherapy in children derives from the 
use of low-dose-rate regimens. However, low-dose-rate brachytherapy is slowly being 
replaced by emerging brachytherapy techniques such as pulsed-dose-rate and high-dose-
rate brachytherapy because of better compliance with radiation safety regulations and 
more sophisticated treatment planning equipment. High-dose-rate brachytherapy has a 
more unfavourable profile of toxic effects compared with low-dose-rate and pulsed-
dose-rate brachytherapy because of the use of larger doses per fraction that restrict the 
repair of late reacting tissues in a growing individual. For that reason, the high-dose-rate 
fractions used in brachytherapy in children (3–4 Gy) are usually smaller than those in 
adults. For instance, the linear quadratic model58 predicts that the high-dose-rate-only 
regimen used at the Ohio State University, Columbus, OH, USA, of 12 3 Gy fractions 
given twice a day (total dose 36 Gy) is equivalent to 39 Gy and 43 Gy delivered with 
standard fractionation (2 Gy per day) assuming standard α/β ratios for acute and late-
reacting tissues of 10 and 3, respectively. If the same total dose of 36 Gy were delivered 
with nine fractions of 4 Gy, the equivalent total dose for late-reacting tissues 
standardised for 2 Gy fractions would rise to 50.4 Gy. 
 
Based on the current level of evidence, brachytherapy cannot be regarded as the gold 
standard for any tumour in children. However, the reported results suggest that it seems 
to be especially suited for children with a soft-tissue sarcoma or rhabdomyosarcoma in 
whom organ preservation and function is a priority and in whom adequate tumour 
reduction can be achieved with resection, multiagent chemotherapy, or both. 
 
In conclusion, brachytherapy, if feasible, is an attractive alternative to conventional 
radiotherapy when radiotherapy is needed for the treatment of children with tumours. 
Brachytherapy probably decreases the probability of late complications, including the 
development of second primary tumours compared with external-beam radiotherapy. 
High-dose-rate and pulsed-dose-rate brachytherapy will probably replace low-dose-rate 
brachytherapy; therefore, fractionation regimens that are biologically equivalent need to 
be developed and long-term effects need to be addressed. 
 
 
SEARCH STRATEGY AND SELECTION CRITERIA 
 
A thorough PubMed search of title words was done between 1966 and 2005, combining 
a set of population-based search terms (pediatric, pediatrics and their homophones, 
paediatric and paediatrics, as well as child, children, and childhood), a set of radiation-
based search terms (brachytherapy or curietherapy), and a set of search terms containing 
specific paediatric tumours (rhabdomyosarcoma, retinoblastoma, etc). There were no 
restrictions on language. 
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Figure 1. Fibrosarcoma in 9-year old boy. Fibrosarcoma in pterygoid space near carotid 
vessels was attached to pterygoid process on left side (arrows). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Recurrent paravertebral sarcoma. (A) Postoperative CT scan showing four 
afterloading catheters (arrows) placed in surgical bed for perioperative high-dose-rate 
brachytherapy. Posterior vertebral arc on right side was removed during surgery 
(asterisk). (B) Oblique view of threedimensional reconstruction at level of upper thorax 
and lower neck shows that brachytherapy isodose surface of 3 Gy (green) mostly spares 
spinal cord (red). 
 
 
 
 
 
 
 
Figure 3. Intraoperative high dose rate brachytherapy for mediastinal 
Lymphadenopathy. A tissue-equivalent applicator (blue plastic material) with two 
afterloading catheters (black arrows) is secured against surgical surface. Applicator was 
positioned between azygos vein (asterisk) and mediastinum after resection of several 
right paratracheal nodes. Lung tissue (white arrows) is displaced from brachytherapy 
area with surgical retractors. 
 
 
 
 
Figure 4. Target volume irradiated with brachytherapy in nasopharyngeal Carcinoma. 
Two flexible applicators (yellow arrows) are inserted through nose. Isodose lines of 3 
Gy (blue circle), 4 Gy (red circle), and 6 Gy (yellow circle) are depicted in CT image. 
Radiotherapy of salivary glands (red solid arrows), masticatory muscles (asterisks), and 
mandible (red dotted arrows) is minimal. 
 
 
 
Figure 5. Alveolar rhabdomyosarcoma treated with brachytherapy after Chemotherapy. 
(A) Postchemotherapy MRI shows partial response (red arrows). (B) Conservative 
resection with perioperative high dose-rate brachytherapy. Colour buttons (arrows) 
secure afterloading catheters in entry and exit points at skin surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Results of low-dose-rate brachytherapy in children with brain tumours 
 
 
 
 
 
Table 2. Results of brachytherapy in children with clear-cell carcinoma, 
craniopharyngioma, Ewing’s sarcoma or primitive neuroectodermal tumours, and 
neuroblastoma 
 
 
 
Table 3. Results of brachytherapy in children with rhabdomyosarcoma 
 
 
 
 
 
Table 4. Results of brachytherapy in children with soft-tissue sarcoma 
 
 
 
 
 
 
